Of note, the combination of Bcl‐2/Bcl‐xL/Bcl‐W antagonists and drugs targeting PDPK1/Akt has thus far not been discussed as a treatment option for pancreatic cancer, further demonstrating the applicability of our model to identify innovative combinatorial approaches. The gene discussed is BCL2L1; the disease is pancreatic neoplasm.